Guardant Health, Inc. (NASDAQ:GH) Holdings Decreased by Northern Trust Corp

Northern Trust Corp lessened its stake in Guardant Health, Inc. (NASDAQ:GH) by 18.1% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,141,992 shares of the company’s stock after selling 251,587 shares during the period. Northern Trust Corp owned 0.92% of Guardant Health worth $34,888,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in GH. R Squared Ltd acquired a new position in shares of Guardant Health during the 4th quarter valued at $26,000. SBI Securities Co. Ltd. acquired a new position in Guardant Health during the fourth quarter worth about $43,000. Kimelman & Baird LLC bought a new stake in Guardant Health in the fourth quarter worth about $58,000. NewEdge Advisors LLC lifted its holdings in Guardant Health by 13.5% in the 4th quarter. NewEdge Advisors LLC now owns 1,929 shares of the company’s stock valued at $59,000 after acquiring an additional 230 shares during the last quarter. Finally, Quantbot Technologies LP bought a new position in shares of Guardant Health during the 4th quarter valued at about $80,000. 92.60% of the stock is currently owned by institutional investors.

Guardant Health Stock Up 0.1 %

GH stock opened at $41.72 on Friday. The firm has a 50 day moving average of $43.72 and a two-hundred day moving average of $38.84. Guardant Health, Inc. has a 12 month low of $20.14 and a 12 month high of $52.92. The company has a market capitalization of $5.17 billion, a price-to-earnings ratio of -11.72 and a beta of 1.49.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.57) by $0.08. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The business had revenue of $203.47 million for the quarter, compared to analyst estimates of $189.91 million. During the same quarter in the prior year, the firm posted ($0.46) EPS. The firm’s revenue for the quarter was up 20.8% on a year-over-year basis. On average, research analysts expect that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Insider Buying and Selling at Guardant Health

In other news, CEO Amirali Talasaz sold 106,784 shares of the stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $49.01, for a total value of $5,233,483.84. Following the completion of the sale, the chief executive officer now directly owns 2,202,672 shares of the company’s stock, valued at approximately $107,952,954.72. This represents a 4.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 107,132 shares of company stock worth $5,249,355 over the last ninety days. Company insiders own 5.50% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on GH. UBS Group increased their target price on shares of Guardant Health from $65.00 to $70.00 and gave the company a “buy” rating in a research note on Thursday, May 1st. Mizuho initiated coverage on Guardant Health in a research report on Thursday, April 10th. They set an “outperform” rating and a $55.00 price objective for the company. Scotiabank restated an “outperform” rating on shares of Guardant Health in a report on Monday. Raymond James reaffirmed an “outperform” rating and set a $59.00 target price (up from $39.00) on shares of Guardant Health in a report on Friday, February 21st. Finally, Barclays lifted their price target on Guardant Health from $55.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, May 1st. Twenty-one analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $52.32.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.